Mission Statement

Recognizing the rapid progress and growing importance of the therapeutic application of nuclear medicine, the Nuclear Medicine Europe Therapy Working Group was established to represent this evolving, cutting-edge sector and to highlight the leading role of all players in the industrial value chain of radiopharmaceutical production for the benefit of patients.

The mission of the Therapy Working Group is based on four fundamental pillars:

  1.  Support the nuclear medicine industry in delivering innovative therapeutic solutions to healthcare professionals and patients.
  2. Establish radioligand therapy (RLT) as a key component among anti-cancer therapies.
  3. Promote equal patient access to the medical benefits of RLT across Europe.
  4. Make RLT affordable through its cost-efficient use of medical resources

In order to achieve this mission the WG Therapy will welcome and include members from companies representing the different actors of the value chain that contribute to bringing the full medical benefit of radiopharmaceuticals to the patients. This approach maximize the expertise developed within our industry.

The WG Therapy will serve as a reference group for the Nuclear Medicine Europe Executive Committee decisions and actions.

The Working Group develops opinions and positions on therapeutic perspectives and works to ensure that these positions are well recognized and incorporated into key policy documents at both the EU and national levels.

When necessary or advised, the WG Therapy will meet with other working groups to discuss issues of shared relevance and foster synergistic activities.

The Group

Chair : Jean Bonnet
Head of Strategy, Sales & Marketing – IRE

Vice-Chair : Jean-François Gestin
Arronax

Supervisor : Lutz Helmke
Vorstand Segment Radiopharma – Eckert & Ziegler


Dirk Bernhardt
VP Global Market Access – ITM Radiopharma

Samy Bertrand
Product Manager – IBA Group

Evelyne Boos
Medical Scientific Director – Curium Group

Jean-Michel Geets
Integralab Business Developer – IBA Group

Alex Gibbs
Head of Global Oncology Policy – Bayer

Dimitry Ginzburg
R&D Manager – Rotem Industries

Ira Goldman 
Vice President, Global Public Policy and Government Relations – Lantheus

Avşar Kumral
Medical Manager – Monrol

Sophie Letournel
Governance and Communication Director – Oranomed

Mario Malinconico
Product Manager & Senior Radiochemist – Comecer

Steven Max
Senior Director – Compound Development Team Leader – Janssen Cilag International

Matteo Melandri
Key Account and Area Manager – Tema Sinergie

Raphael Ortiz
Chief Operating Officer – Telix Pharmaceuticals

Jasminka Taleska
Global Director RLT Policy strategy – AAA Novartis

Guy Turquet de Beauregard
Honorary President – NMEU

Corentin Warnier
Head of Chemistry – Trasis

Adrien Reymond
Business Development and Regulatory Affairs Director – Atonco

Lorenzo Pompignoli
Tema SinergieSales Engineer

Akiharu Otaka
General Manager, BD & IP Department, R&D Division -Nihon Medi Physics 

Govert de With
Manager Radiation Protection R&I
NRG Pallas

Benjamin FELIX
Technical Director Nuclear Medicine – Chief Information Officer
Lemer Pax

Shopping Basket